Closing the Marketing Strategy-Tactics Gap: An Institutional Theory Analysis of Pharmaceutical Value Chain

[1]  Katharina Burger,et al.  Organizations Rational Natural And Open Systems , 2016 .

[2]  Michael Frueh.  The Truth About The Drug Companies How They Deceive Us And What To Do About It , 2016 .

[3]  Iwao Hirose,et al.  Arrow, Kenneth J. , 2014 .

[4]  Jagdip Singh,et al.  When Institutional Work Backfires: Organizational Control of Professional Work in the Pharmaceutical Industry , 2013 .

[5]  Peter W Carmel.  Restrictions on use of prescribing data for drug promotion. , 2012, The New England journal of medicine.

[6]  Ian Wilkinson,et al.  Toward a normative theory of normative marketing theory , 2005, ArXiv.

[7]  Catholijn M. Jonker,et al.  Shared Mental Models - A Conceptual Analysis , 2010, COIN@AAMAS&MALLOW.

[8]  C. Flanagan,et al.  TIES THAT BIND : CORRELATES OF ADOLESCENTS' CIVIC COMMITMENTS IN SEVEN COUNTRIES , 2010 .

[9]  T. Insel,et al.  Psychiatrists' relationships with pharmaceutical companies: part of the problem or part of the solution? , 2010, JAMA.

[10]  David Orentlicher.  Prescription Data Mining and the Protection of Patients' Interests , 2010, Journal of Law, Medicine & Ethics.

[11]  R. P. Mills,et al.  A perspective on commercial relationships between ophthalmology and industry. , 2009, Archives of ophthalmology.

[12]  Michel Lander,et al.  Structure! Agency! (And Other Quarrels): A Meta-Analysis Of Institutional Theories Of Organization , 2009 .

[13]  Michel Lander,et al.  Structure! Agency! (And Other Quarrels): Meta-Analyzing Institutional Theories of Organization , 2009 .

[14]  Marcia Angell,et al.  Industry-sponsored clinical research: a broken system. , 2008, JAMA.

[15]  H. Krumholz,et al.  The ADVANTAGE Seeding Trial: A Review of Internal Documents , 2008, Annals of Internal Medicine.

[16]  Raghunath Singh Rao,et al.  The Fruits of Legitimacy: Why Some New Ventures Gain More from Innovation Than Others. , 2008 .

[17]  P. de Jonge,et al.  Selective publication of antidepressant trials. , 2008, The New England journal of medicine.

[18]  A. Fugh-Berman.  Prescription Tracking and Public Health , 2008, Journal of General Internal Medicine.

[19]  Harlan M Krumholz,et al.  Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. , 2008, JAMA.

[20]  R. Kronmal,et al.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. , 2008, JAMA.

[21]  Devon S. Johnson,et al.  Is Firm Trust Essential in a Trusted Environment? how Trust in the Business Context Influences Customers , 2008 .

[22]  R. Steinbrook.  Financial support of continuing medical education. , 2008, JAMA.

[23]  Richard G. McFarland,et al.  Supply Chain Contagion , 2008 .

[24]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[25]  Joel Lexchin,et al.  The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.

[26]  Sowmya R. Rao,et al.  Institutional academic industry relationships. , 2007, JAMA.

[27]  M. Steinman,et al.  Is continuing medical education a drug-promotion tool?: YES. , 2007, Canadian family physician Medecin de famille canadien.

[28]  Sriram Venkataraman,et al.  The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..

[29]  D. Grande.  Prescriber Profiling: Time to Call It Quits , 2007, Annals of Internal Medicine.

[30]  J. Greene.  Pharmaceutical Marketing Research and the Prescribing Physician , 2007, Annals of Internal Medicine.

[31]  T. Brennan,et al.  Sunshine laws and the pharmaceutical industry. , 2007, JAMA.

[32]  David J. Collis,et al.  Strategy in the Twenty First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. , 2006 .

[33]  John Carreyrou.  Cephalon used improper tactics to sell drug, probe finds. , 2006, Wall Street journal.

[34]  Reed Abelson.  New nerve test, a moneymaker, divides doctors. , 2006, The New York times on the Web.

[35]  C. Natanson,et al.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. , 2006, The New England journal of medicine.

[36]  C. Deangelis.  The influence of money on medical science. , 2006, JAMA.

[37]  M. Chren,et al.  Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents , 2006, Annals of Internal Medicine.

[38]  Jan B. Heide,et al.  Friends, Businesspeople, and Relationship Roles: A Conceptual Framework and a Research Agenda , 2006 .

[39]  S. Clegg.  The SAGE Handbook of Organization Studies , 2006 .

[40]  R. Steinbrook,et al.  For sale: physicians' prescribing data. , 2006, The New England journal of medicine.

[41]  T. Lawrence,et al.  Institutions and Institutional Work , 2006 .

[42]  Jeffrey Q. Barden,et al.  Cognitive Underpinnings of Institutional Persistence and Change: A Framing Perspective , 2006 .

[43]  Jordan J. Cohen,et al.  Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. , 2006, JAMA.

[44]  Don A. Moore,et al.  Conflicts Of Interest And The Case Of Auditor Independence: Moral Seduction And Strategic Issue Cycling , 2006 .

[45]  A. Wazana,et al.  Physicians and the Pharmaceutical Industry , 2006 .

[46]  T. Tyler,et al.  Psychological perspectives on legitimacy and legitimation. , 2006, Annual review of psychology.

[47]  Anna Wilde Mathews.  Ghost story: at medical journals, writers paid by industry play big role. , 2005, Wall Street journal.

[48]  S. Hill,et al.  Ties that bind: multiple relationships between clinical researchers and the pharmaceutical industry. , 2005, Archives of internal medicine.

[49]  Pradeep K. Chintagunta,et al.  Temporal Differences in the Role of Marketing Communication in New Product Categories , 2005 .

[50]  J. Annan,et al.  Situational Analysis , 2005 .

[51]  J. Moncrieff,et al.  Psychiatry and the pharmaceutical industry: Who pays the piper? , 2005 .

[52]  David L. Deephouse,et al.  An Examination of Differences between Organizational Legitimacy and Organizational Reputation , 2005 .

[53]  J. M. Thomas.  Studdert DM, Mello MM, Brennan TA. Financial conflicts of interest in physicians' relationships with the pharmaceutical industry-self-regulation in the shadow of federal prosecution. N Engl J Med. 2004;351:1891-1900. , 2005 .

[54]  Elisabeth Honka,et al.  The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. , 2005, Yale journal of health policy, law, and ethics.

[55]  Natalie Mizik,et al.  Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..

[56]  T. Brennan,et al.  Financial Conflicts of Interest in Physicians' Relationships with the Pharmaceutical Industry — Self-Regulation in the Shadow of Federal Prosecution , 2004 .

[57]  Sridhar Narayanan,et al.  Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions , 2004 .

[58]  Pradeep K. Chintagunta,et al.  Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis , 2004 .

[59]  Oliver Richard,et al.  Persistence in prescriptions of branded drugs , 2004 .

[60]  Iain J. Clelland,et al.  Talking Trash: Legitimacy, Impression Management, and Unsystematic Risk in the Context of the Natural Environment , 2004 .

[61]  T. Carson.  Conflicts of Interest and Self-Dealing in the Professions: A Review Essay , 2004, Business Ethics Quarterly.

[62]  M. Angell.  The Truth About the Drug Companies: How They Deceive Us and What to Do About It , 2004 .

[63]  Carol A Caronna.  The misalignment of institutional "pillars": consequences for the U.S. health care field. , 2004, Journal of health and social behavior.

[64]  L. Stalley,et al.  The Influence of the Pharmaceutical Industry , 2004 .

[65]  D. Antonuccio,et al.  Psychology in the prescription era: building a firewall between marketing and science. , 2003, The American psychologist.

[66]  M. Arthur.  Share Price Reactions to Work-Family Initiatives: An Institutional Perspective , 2003 .

[67]  D. Healy,et al.  Interface between authorship, industry and science in the domain of therapeutics , 2003, British Journal of Psychiatry.

[68]  Carl T. Bergstrom,et al.  The Red King effect: When the slowest runner wins the coevolutionary race , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Rajdeep Grewal,et al.  The Role of the Institutional Environment in Marketing Channels , 2002 .

[70]  D. Rennie,et al.  Prevalence of honorary and ghost authorship in Cochrane reviews. , 2002, JAMA.

[71]  A. Detsky,et al.  Relationships between authors of clinical practice guidelines and the pharmaceutical industry. , 2002, JAMA.

[72]  Füsun F. Gönül,et al.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .

[73]  Eliot Freidson,et al.  Professionalism: The Third Logic , 2001 .

[74]  A. Relman,et al.  Separating continuing medical education from pharmaceutical marketing. , 2001, JAMA.

[75]  J. Lampel,et al.  Probing the Unobtrusive Link: Dominant Logic and the Design of Joint Ventures at General Electric , 2000 .

[76]  A. Wazana,et al.  Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.

[77]  Michael Ahearne,et al.  If looks could sell: Moderation and mediation of the attractiveness effect on salesperson performance , 1999 .

[78]  A. Lewin,et al.  Prolegomena on Coevolution: a Framework for Research on Strategy and New Organizational Forms , 1999 .

[79]  W. Scott,et al.  A Multidimensional Model of Organizational Legitimacy: Hospital Survival in Changing Institutional Environments , 1998 .

[80]  Johan P. Olsen,et al.  The Institutional Dynamics of International Political Orders , 1998, International Organization.

[81]  D. Rennie,et al.  Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. , 1998, JAMA.

[82]  Paul DiMaggio.  Culture and cognition , 1997 .

[83]  J. March.  Continuity and Change in Theories of Organizational Action , 1996 .

[84]  Robert N. Stern,et al.  Organizations and Social Systems: Organization Theory's Neglected Mandate. , 1996 .

[85]  Mark C. Suchman.  Managing Legitimacy: Strategic and Institutional Approaches , 1995 .

[86]  W. Scott,et al.  Institutions and Organizations. , 1995 .

[87]  J. Barney,et al.  Trustworthiness as a Source of Competitive Advantage , 1994 .

[88]  D. North,et al.  Elements of Reason: Shared Mental Models: Ideologies and Institutions , 1994 .

[89]  W. Powell,et al.  The New Institutionalism in Organizational Analysis , 1993 .

[90]  J. Boatright.  Conflict of Interest: An Agency Analysis , 1992 .

[91]  M. Goldstein.  Physicians and the pharmaceutical industry. , 1990, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[92]  C. Oliver.  STRATEGIC RESPONSES TO INSTITUTIONAL PROCESSES , 1991 .

[93]  R. Zeckhauser,et al.  Principals and Agents: The Structure of Business , 1990 .

[94]  A. Giddens.  The consequences of modernity , 1990 .

[95]  H. Thomas,et al.  Competitive Groups as Cognitive Communities: The Case of Scottish Knitwear Manufacturers Revisited , 1989 .

[96]  Sung-Kuon Chi,et al.  Ethics and agency theory , 1989 .

[97]  M. Bowman,et al.  Changes in drug prescribing patterns related to commercial company funding of continuing medical education. , 1988, The Journal of continuing education in the health professions.

[98]  S. Shapiro.  The Social Control of Impersonal Trust , 1987, American Journal of Sociology.

[99]  C. Prahalad,et al.  The dominant logic: A new linkage between diversity and performance , 1986 .

[100]  K. Arrow.  The Economics of Agency. , 1984 .

[101]  Conrad Seipp,et al.  The Social Transformation of American Medicine. , 1984 .

[102]  J. Kett,et al.  The Social Transformation of American Medicine , 1983 .

[103]  Donald L. Mills,et al.  Organizations: Rational, Natural and Open Systems , 1983 .

[104]  G. Domhoff,et al.  C. Wright Mills and The power elite , 1968 .

[105]  W. Bennis,et al.  The Social Psychology of Organizations , 1966 .

[106]  Talcott Parsons,et al.  The Distribution of Power in American Society , 1957, World Politics.

[107]  T. Parsons.  SUGGESTIONS FOR A SOCIALOGICAL APPROCH TO THE THEORY OF ORGANIZATIONS , 1956 .

[108]  W. Powell,et al.  The iron cage revisited institutional isomorphism and collective rationality in organizational fields , 1983 .